Skip to content
lifestyle.luxedb.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
July 21, 2026
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
July 20, 2026
Dyne Therapeutics Appoints Barry Greene to Board of Directors
June 22, 2026
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 18, 2026
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
June 17, 2026
Dyne Therapeutics to Participate in Upcoming Investor Conferences
May 13, 2026
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 11, 2026
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
April 27, 2026
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 23, 2026
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
March 2, 2026
←
Previous Page
1
2
3
Next Page
→